ArticleFrontiers in endocrinology2025
Circulating bile acids and HOMA-IR: cross-sectional results from the RoCAV population-based study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- Longitudinal multi-omic dynamics in hospitalized COVID-19 patients based on disease severity.Gut microbes reports · 2026Article
- The Metabolic Mind: Revisiting Glucose Metabolism and Justice Involvement in Neurolaw.NeuroSci · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating bile acids (cBAs) function as signaling molecules that activate the farnesoid X receptor (FXR), promoting the secretion of fibroblast growth factor 19 (FGF-19), a gut-derived hormone involved in bile acid (BA) synthesis, glucose metabolism, and insulin sensitivity. However, the relationship between fasting cBAs, FGF-19, and insulin resistance-as estimated by HOMA-IR-remains unclear. This study explored these associations in an elderly population from Northern Italy. Material and methods: We examined a subsample of 1080 subjects (aged 60-75 years, 1:1 male-to-female ratio) from the RoCAV population-based study (2013-2016). Fasting blood samples were analyzed for 33 cBAs using UHPLC-MS/MS, of which 23 met quality criteria. FGF-19 levels were also measured. After excluding individuals with missing data or fibrate therapy, 1049 participants were included. Associations between cBAs, FGF-19, and HOMA-IR were assessed via linear regression, adjusting for age, sex, BMI, diet, alcohol intake, hypertension, and dyslipidemia. ROC curve analysis evaluated the ability of cBAs and FGF-19 to discriminate T2DM cases. Results: After excluding participants with missing anthropometric and clinical data or in fibrate treatment, data from 1049 subjects (mean±SD age 68.6±4.5 years, males 49.5%, T2DM 10.6%) were analysed. FGF-19 showed a positive correlation with primary cBAs (Spearman's ρ=0.33, p<0.001). Adjusted for covariates, both primary and secondary cBAs were positively associated with HOMA-IR (β=0.07, p=5×10 Conclusions: In this elderly Italian population, primary and secondary cBAs were positively associated with insulin resistance, after adjusting for each other, whereas FGF-19 negatively. These markers may enhance T2DM risk stratification and may give insights on bile acid-glucose metabolism links.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.